COREY POTTER: Open Payments
NPI 1992182414 · PROVIDENCE, RI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,150 in 46 payments from 7 companies in 2025. Trend: 2023 $2,006 · 2024 $2,986 · 2025 $1,150
Food & beverage: $1,150
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 14 | $278 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $258 |
| ABBVIE INC. | 8 | $193 |
| Axsome Therapeutics, Inc. | 7 | $187 |
| Vanda Pharmaceuticals Inc. | 3 | $156 |
| E.R. Squibb & Sons, L.L.C. | 2 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
Products named: CAPLYTA, VRAYLAR, Auvelity, AUSTEDO XR, FANAPT, UZEDY, COBENFY, TRINTELLIX.
Industry payments across RI — which companies pay providers there.
